On the other hand, the addition of Liraglutide to cells exposed to hyperglycemia and oxidative stress caused a decrease in pAKT/AKT levels, preventing ECM overproduction, and restored NO production via iNOS-minimizing oxidative stress damage. Here, AKT1 is linked to Hyperglycemia.